Propofol and Isoflurane effects in thoracic surgeries

The comparison of Propofol and Isoflurane on arterial oxygenation pressure, mean arterial pressure and heart rate variations following one-lung ventilation in thoracic surgeries

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013122615942N1

Enrollment

Registered

2014-02-03

Start date

2012-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anasthesia. Anaesthetic, unspecified

Interventions

Intervention 1: Intervention group: Propofol (100 µg/kg/min), During Surgery. Intervention 2: Control group: one Mac (1.1%) Isoflurane, During surgery.

Prevention

Intervention group: Propofol (100 µg/kg/min), During Surgery

Control group: one Mac (1.1%) Isoflurane, During surgery

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The major inclusion criteria: The age range of 18-75 years old; ASA class I (Healthy person) and III (Severe systemic disease); The consent to undergo thoracic surgery with OLV, according to the study conditions The major exclusion criteria: Liver malfunction (Aspartate transaminase (AST) more than 40, Alanine transaminase (ALT) more than 40); Ischemic or valvular heart disease (history of cardiovascular diseases, physical status, Electrocardiogram (EKG) and echocardiography of the patients were analyzed); Recent use of anesthetic medications; Obstructive and end-stage restrictive pulmonary disease; Patients with one-lung ventilationin (OLV) less than 30 min; Patients with End -Tidal CO2 (ETCO2) more than 45 mmHg, and the respiratory rate of 12 breaths per minute; Patients who have pathological problems in the left lung (pulmonary), according to High Resolution Computed Tomography (HRCT) and pulmonary function tests (PFT) before the surgery.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mean pressure of arterial oxygen. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.;Mean Arterial pressure. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.;Heart Rate. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.	—

Measure

Time frame

Mean pressure of arterial oxygen. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.;Mean Arterial pressure. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.;Heart Rate. Timepoint: During two lung ventilation and in 5, 10 and 20 minute after one lung ventilation. Method of measurement: ABG Test by GEM premier 3000.

—

Secondary

Measure	Time frame
Arterial oxygen saturation. Timepoint: During ventilation of two lungs, 5, 10 and 20 minute after one lung ventilation. Method of measurement: Monitoring.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Rahnamazadeh

Ghaem Hospital

rahnamazadehm891@mums.ac.ir+98 51 1768 7898

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026